Health Canada approves Maviret for pangenotypic chronic HCV

Health Canada approved AbbVie’s Maviret for treating adults with chronic hepatitis C for all genotypes, according to a press release. Maviret is designated for patients without cirrhosis and who are new to treatment.

“With the approval of Maviret, we are proud to bring the hope of a new cure to people living with hepatitis C in Canada, reflecting AbbVie’s dedication to addressing critical unmet needs for patients,” Stéphane Lassignardie, general manager of AbbVie Canada, said in the release. “Maviret is designed to deliver a virologic cure for most HCV patients including those with specific treatment challenges. AbbVie will continue to work with local health authorities and stakeholders across Canada to get our treatment to as many patients as possible.”

Maviret (glecaprevir/pibrentasvir, AbbVie) is also approved for patients with compensated cirrhosis, severe chronic kidney disease, those with genotype 1 who were not previously cured with certain direct-acting antiviral treatment, and those with genotype 3 chronic HCV.

Canadian patients prescribed Maviret may also enroll in AbbVie Care, AbbVie’s patient support program designed to provide services such as reimbursement assistance, education and ongoing disease management support.

Reference: www.abbvie.ca

Health Canada approved AbbVie’s Maviret for treating adults with chronic hepatitis C for all genotypes, according to a press release. Maviret is designated for patients without cirrhosis and who are new to treatment.

“With the approval of Maviret, we are proud to bring the hope of a new cure to people living with hepatitis C in Canada, reflecting AbbVie’s dedication to addressing critical unmet needs for patients,” Stéphane Lassignardie, general manager of AbbVie Canada, said in the release. “Maviret is designed to deliver a virologic cure for most HCV patients including those with specific treatment challenges. AbbVie will continue to work with local health authorities and stakeholders across Canada to get our treatment to as many patients as possible.”

Maviret (glecaprevir/pibrentasvir, AbbVie) is also approved for patients with compensated cirrhosis, severe chronic kidney disease, those with genotype 1 who were not previously cured with certain direct-acting antiviral treatment, and those with genotype 3 chronic HCV.

Canadian patients prescribed Maviret may also enroll in AbbVie Care, AbbVie’s patient support program designed to provide services such as reimbursement assistance, education and ongoing disease management support.

Reference: www.abbvie.ca